Grace Therapeutics, Inc. Increase (Decrease) in Other Operating Assets and Liabilities, Net
Grace Therapeutics, Inc. (GRCE) reported Increase (Decrease) in Other Operating Assets and Liabilities, Net of $2.49 million for the 6-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet · last filed 2023-11-13
- Grace Therapeutics, Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2023-09-30 was $4.51M, a 220.67% increase year-over-year.
- Grace Therapeutics, Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2023-06-30 was -$2.03M.
- Grace Therapeutics, Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2022-09-30 was $1.41M.
- Grace Therapeutics, Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2022-06-30 was -$1.27M.
- Grace Therapeutics, Inc. increase (decrease) in other operating assets and liabilities, net for fiscal 2023 was -$181.00K, a 106.50% decline from fiscal 2022.
- Grace Therapeutics, Inc. increase (decrease) in other operating assets and liabilities, net for fiscal 2022 was $2.79M.
| Period end | Increase (Decrease) in Other Operating Assets and Liabilities, Net 3 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 6 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 12 month |
|---|---|---|---|
| 2023-09-30 | $4.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-13 | $2.49M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | -$2.03M 10-Q · filed 2023-08-11 | ||
| 2023-03-31 | -$181.00K 10-K · filed 2023-06-23 | ||
| 2022-09-30 | $1.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-13 | $137.00K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | -$1.27M 10-Q · filed 2023-08-11 | ||
| 2022-03-31 | $2.79M 10-K · filed 2023-06-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |